Seneca Biopharma, Inc. (SNCA) News
Filter SNCA News Items
SNCA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SNCA News Highlights
- For SNCA, its 30 day story count is now at 6.
- Over the past 27 days, the trend for SNCA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about SNCA are BIO, SAFE and STAY.
Latest SNCA News From Around the Web
Below are the latest news stories about Seneca Biopharma Inc that investors may wish to consider to help them evaluate SNCA as an investment opportunity.
Seneca Biopharma Announces Successful Approval of Merger with Leading Biosciences, Inc.Seneca Biopharma, Inc. (Nasdaq: SNCA) ("Seneca" or the "Company"), disclosed on April 23, 2021, the passing of the final proposal required for approval of the proposed merger between Seneca and Leading Biosciences, Inc. ("LBS"). The Merger is expected to close on or about April 27, 2021 and the new combined company, Palisades Bio, is expected to begin trading on the Nasdaq Capital Market on or about April 28, 2021 under the ticker "PALI". |
Today’s Biggest Pre-Market Movers: 10 Top Gainers and Losers on Thursday MorningThursday's here and we're taking a look at the biggest pre-market movers investors will want to know about before the opening bell. |
Leading BioSciences Announces Early Efficacy Signal in Reducing Post-Surgical Adhesions in Open Label StudyCARLSBAD, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Leading BioSciences, Inc. (“LBS” or "the Company"), a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca Biopharma, Inc. (Nasdaq: SNCA), subject to certain conditions to be completed, to form Palisade Bio, Inc., announced data from an open label GI surgery study with lead asset LB1148 that provided an early indication of efficacy signal in reducing post-surgical adhesions following elective bowel resection. No abdominal adhesions were observed at the time of a follow-up surgery in two patients treated with LB1148. Although these are early data in a limited number of patients, the data may support the Company's ongoing Phase 2 clinical trial to evaluate the impact of LB1148 on retu... |
Leading BioSciences Releases Video Message Encouraging Seneca Biopharma, Inc. Stockholders to Vote at the Virtual Special Meeting on April 23, 2021Video messages urges Seneca stockholders to vote in support of Proposal #1, the reverse stock split, in order to approve the proposed transaction. Proposal 1 was favored by a wide margin by Seneca stockholders who voted at the virtual Special Meeting on April 9, 2021. CARLSBAD, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Leading BioSciences, Inc. (“LBS”), a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal complications, today released a video message from its CEO, Dr. Tom Hallam, to address the status of the proposed merger transaction with Seneca Biopharma, Inc. (Nasdaq: SNCA) (“Seneca”). All proposals, with the exception of Proposal #1, the reverse stock split (the “Reverse Split Proposal”), have been approved by Seneca stockholders. The Reverse S... |
Seneca Biopharma, Inc. Announces (i) Voting Results from the Special Meeting of Stockholders and (ii) New Special Meeting Date of April 23, 2021Seneca Biopharma, Inc. (Nasdaq: SNCA) ("Seneca" or the "Company"), announced the preliminary voting results of its Special Meeting of Stockholders on April 9, 2021. At the Special Meeting, Seneca asked stockholders to approve six proposals related to its proposed merger transaction with Leading BioSciences, Inc. ("LBS"), a biopharma company advancing therapies for acute and chronic gastrointestinal complications. All proposals, with the exception of proposal #1 for a reverse stock split (the "Reverse Split Proposal"), were approved by Seneca stockholders. In order to solicit additional votes for the Reverse Split Proposal, the Special Meeting was adjourned only with respect to the Reverse Split Proposal until April 23, 2021 at 11:00 AM ET and will be held virtually at www.virtualshareho... |
Leading BioSciences Releases Video Message Highlighting Compelling Investment Thesis of Proposed Merger with Seneca Biopharma, Inc.Video message explains the multiple benefits of the proposed merger and provides an overview of the substantial market opportunity for the combined company to be named Palisade Bio Seneca stockholders are urged to vote in support of the merger by voting FOR each proposal presented at Seneca’s Special Meeting on April 9, 2021, including approval of a reverse stock split which is a key condition to closing CARLSBAD, Calif., April 02, 2021 (GLOBE NEWSWIRE) -- Leading BioSciences, Inc. (“LBS”), a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, today released a video message from its CEO, Tom Hallam, highlighting the many compelling attributes of the proposed merger with Seneca Biopharma, Inc. (Nasdaq: SNCA) (“Seneca”). Seneca stock... |
Seneca Stockholder LetterTo Our Valued Stockholders: |
Seneca Biopharma Reports 2020 Yearend ResultsSeneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today reported its financial results for the year ended December 31, 2020. |
Thinking about buying stock in Support.com, Seneca Biopharma, Hall of Fame Resort & Entertainment, Dyadic International, or Stonemor?NEW YORK, March 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SPRT, SNCA, HOFV, DYAI, and STON. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding… |
Seneca Biopharma Inc $SNCA: Cash per share is equal to $2, and the stock price is $1.64!Business Profile Headquartered in Germantown, MARYLAND, Seneca Biopharma Inc (SNCA) reports a market capitalization of $28 million, and sells shares |